PRESS RELEASE
Gedea Biotech today announced that the company has been granted a US patent for its vaginal formulation (patent no. 12,496,288). The patent marks an important step for Gedea Biotech in protecting the product on the US market and is expected to be of high strategic value for future collaboration partners.
The newly granted patent provides protection for the formulation of the active ingredient, glucono delta-lactone (GDL), in pHyph, the company’s vaginal tablet for the treatment of vaginal infections. The patent broadens the company’s intellectual property protection of pHyph as it covers the formulation of GDL and its use for treatment of any microbial infection, hereunder vaginal infections.
“This US patent represents another key milestone for Gedea as we continue to strengthen our IP position globally,” said Annette Säfholm, CEO at Gedea Biotech. “The protection of our vaginal formulation in the US market is particularly valuable as we expand our partnering activities and bring pHyph to a wider international market.”
The patent was granted by the United States Patent and Trademark Office (USPTO) and Patents from the same patent family have previously been granted in e.g. Europe, Japan. China, South Korea and Malaysia.